Market revenue in 2023 | USD 467.3 million |
Market revenue in 2030 | USD 824.6 million |
Growth rate | 8.5% (CAGR from 2023 to 2030) |
Largest segment | Coronary stents |
Fastest growing segment | Accessory Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Intravascular Imaging Catheters and Pressure Guidewires, Coronary Stents, PTCA Balloon Catheters, Accessory Devices |
Key market players worldwide | Abbott Laboratories, Medtronic PLC, Boston Scientific Corp, Koninklijke Philips NV, Cardinal Health Inc, Terumo Corp, Teleflex Inc, B. Braun, Biosensors, BIOTRONIK, Asahi Intecc Co Ltd, Cook Medical, Merit Medical Systems Inc, Haemonetics Corp, Vascular Solutions, Zeon Corp, Alvimedica, Meril Life, Medinol |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to interventional cardiology devices market will help companies and investors design strategic landscapes.
Coronary stents was the largest segment with a revenue share of 50.33% in 2023. Horizon Databook has segmented the Japan interventional cardiology devices market based on intravascular imaging catheters and pressure guidewires, coronary stents, ptca balloon catheters, accessory devices covering the revenue growth of each sub-segment from 2018 to 2030.
Japan's market for interventional cardiology devices is experiencing notable growth, driven by several key factors. The country's aging population, coupled with the increasing prevalence of cardiovascular diseases, has impelled the demand for advanced medical technologies and treatments.
As a result, there has been a significant adoption of interventional cardiology procedures, such as PCI and angioplasty, across Japan. For instance, as reported in a study published by The Lancet in March 2022, annually over 200,000 PCI procedures are undertaken in Japan.
In Japan, the regulatory framework for interventional cardiology devices is overseen by the Pharmaceuticals and Medical Devices Agency (PMDA), which is responsible for evaluating and approving medical devices for safety & efficacy. The PMDA ensures that interventional cardiology devices meet rigorous standards before they can be marketed and used in Japan.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan interventional cardiology devices market , including forecasts for subscribers. This country databook contains high-level insights into Japan interventional cardiology devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account